Avalon Investment & Advisory’s Charles River Laboratories CRL Stock Holding History

Avalon Investment & Advisory’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-753	Closed	-$214K	–	320
2022 Q1	$214K	Sell	753 -35,465	-98%	-$10.9M	0.01%	306
2021 Q4	$13.6M	Sell	36,218 -6,204	-15%	-$2.41M	0.34%	88
2021 Q3	$17.5M	Buy	42,422 +2,097	+5%	+$871K	0.41%	75
2021 Q2	$14.9M	Sell	40,325 -18,468	-31%	-$6.17M	0.33%	99
2021 Q1	$17M	Buy	58,793 +232	+0.4%	+$64.5K	0.39%	94
2020 Q4	$14.6M	Buy	58,561 +535	+0.9%	+$127K	0.3%	104
2020 Q3	$13.1M	Sell	58,026 -2,530	-4%	-$525K	0.29%	108
2020 Q2	$10.6M	Sell	60,556 -7,408	-11%	-$1.18M	0.24%	117
2020 Q1	$8.58M	Buy	+67,964	New	+$10.2M	0.22%	121

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avalon Investment & Advisory's CRL Position: Q2 2022 in Review

Avalon Investment & Advisory sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 753 shares — an estimated $214K sold.

Avalon Investment & Advisory first reported a position in CRL in Q1 2020 and held it in 9 quarters. The position peaked at $17.5M in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

Avalon Investment & Advisory reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
Avalon Investment & Advisory sold 753 Charles River Laboratories shares in Q2 2022, an estimated $214K.
Avalon Investment & Advisory first reported a position in Charles River Laboratories in Q1 2020 and held it in 9 quarters.
Avalon Investment & Advisory's Charles River Laboratories position peaked at $17.5M in Q3 2021.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Avalon Investment & Advisory's 13F filing for Q2 2022, filed 10 Aug 2022.